Literature DB >> 10782630

Additive effect of latanoprost to the combination of timolol and dorzolamide.

R Susanna1, M T Nicolela, E Oga.   

Abstract

PURPOSE: To study the additive effect of latanoprost 0.005% in patients who have uncontrolled intraocular pressure (IOP) using timolol 0.5% and dorzolamide 2%.
METHODS: Fifty-two consecutive patients with open-angle glaucoma who were using timolol and dorzolamide and were considered to have IOP above their defined target pressure were included in this study. After a baseline diurnal tension curve (DTC) was performed, latanoprost once a day was added to the treatment, and a second DTC was performed 1 week later.
RESULTS: Five patients (9.6%) were discontinued from treatment because of side effects. The remaining 47 patients showed a significant IOP reduction of 3.1 mm Hg (16%) from a baseline of 19.3 mm Hg (mean IOP registered during DTC; P < or = 0.0001). Seventeen patients (36.3%) showed a mean IOP reduction greater than 20%.
CONCLUSIONS: Latanoprost had an additive effect when used as a third drug for patients on timolol and dorzolamide who were in need of further IOP reduction. These results suggest that latanoprost may be very effective in some patients with poorly controlled glaucoma on multiple therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782630     DOI: 10.1097/00061198-200004000-00010

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  3 in total

1.  Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.

Authors:  Tin Aung; Paul T K Chew; Francis T S Oen; Yiong-Huak Chan; Lennard H Thean; Leonard Yip; Boon-Ang Lim; Jade Soh; Steve K L Seah
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 3.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.